Vir Biotechnology (VIR)
(Real Time Quote from BATS)
$5.12 USD
-0.06 (-1.16%)
Updated Sep 19, 2025 12:48 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Vir Biotechnology, Inc. has a PEG ratio of 0.29 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.16.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VIR 5.12 -0.06(-1.16%)
Will VIR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Other News for VIR
VIR Crossed Above 20 Day Moving Average on September 18
20 Day Moving Average Resistance appears for VIR after 1.23% move
Is VIR poised for a decline? 20 Day Moving Average Resistance shows up after rising 1.46%
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Is VIR preparing to trend lower? Fell Below 20 Day Moving Average shows up after sliding 4.2%